Zobrazeno 1 - 10
of 10
pro vyhledávání: '"D I, Twito"'
Autor:
D I Twito, S L Johansson, T R Buroker, Daniel J. Schaid, D H Gesme, M A Flaum, Edward T. Creagan, Michael H. Veeder, L. H. Geeraerts, P S Johnson
Publikováno v:
Journal of Clinical Oncology. 9:2104-2109
We performed a prospective, controlled trial of recombinant leukocyte A interferon (IFN-alpha 2A) with or without aspirin (ASA) in 176 patients with assessable advanced renal cell cancer in light of a 34% response rate (10 of 29 patients) from the tw
Autor:
S F Brunk, Robert F. Marschke, Michael H. Veeder, James A. Mailliard, L K Everson, D I Twito, James R. Jett, Robert J. Dalton, James E. Krook, Terry M. Therneau
Publikováno v:
Journal of Clinical Oncology. 8:33-38
In this randomized study involving patients with limited-stage small-cell lung cancer (LD-SCC), we compared treatment with either cyclophosphamide; doxorubicin, and vincristine (CAV) or CAV plus etoposide (CAVE). All patients received identical thora
Autor:
T E, Elliott, R P, Dinapoli, J R, O'Fallon, J E, Krook, J D, Earle, R F, Morton, R, Levitt, L K, Tschetter, B W, Scheithauer, D M, Pfeifle, D I, Twito, R A, Nelimark
Publikováno v:
Journal of neuro-oncology. 33(3)
We performed a randomized trial to compare survival distributions and toxicity of radiation therapy (RT) and DBD with RT and BCNU in patients with high-grade astrocytoma.A total of 238 patients with supratentorial grade 3 and grade 4 astrocytoma were
Autor:
James R. Jett, Carl G. Kardinal, John Q. Su, Andrew Maksymiuk, D I Twito, James A. Mailliard, Loren K. Tschetter, James B. Gerstner, James E. Krook, Ralph Levitt
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 12(11)
PURPOSE We evaluated the effect of recombinant interferon gamma (rIFN-gamma) on survival and toxicity in small-cell lung cancer (SCLC) patients in complete remission (CR). PATIENTS AND METHODS One hundred patients in CR following treatment with six c
Autor:
J A, Laurie, R G, Hahn, T M, Therneau, S R, Patel, J A, Mailliard, H E, Windschitl, D I, Twito, R F, Morton, J E, Krook
Publikováno v:
Cancer. 69(6)
One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomyc
Autor:
J E, Krook, M J, O'Connell, H S, Wieand, R W, Beart, J E, Leigh, J W, Kugler, J F, Foley, D M, Pfeifle, D I, Twito
Publikováno v:
Cancer. 67(10)
This study evaluated combined 5-fluorouracil (5FU) and doxorubicin as postoperative adjuvant chemotherapy for patients who had undergone potentially curative resection of a primary gastric adenocarcinoma. One hundred twenty-five eligible and evaluabl
Autor:
J N, Ingle, D I, Twito, D J, Schaid, S A, Cullinan, J E, Krook, J A, Mailliard, L K, Tschetter, H J, Long, J G, Gerstner, H E, Windschitl
Publikováno v:
Cancer. 67(4)
A randomized trial was performed to determine if therapy with tamoxifen (TAM) plus fluoxymesterone (FLU) was more efficacious than TAM alone for postmenopausal women with metastatic breast cancer. Patients failing TAM could subsequently receive FLU.
Autor:
JN Ingle, H E Windschitl, D I Twito, David L. Ahmann, James E. Krook, M N Chang, Harry F. Bisel, T P Kubista, L K Everson, Green Sj
Publikováno v:
Journal of Clinical Oncology. 4:178-185
A randomized clinical trial was performed to compare the efficacy of bilateral oophorectomy with that of tamoxifen at a dose of 10 mg twice daily in premenopausal women with metastatic breast cancer, and to examine the efficacy of each as a crossover
Autor:
James E. Krook, Robert F. Marschke, James N. Ingle, S A Cullinan, D I Twito, Daniel J. Schaid, James G. Gerstner, Harry J. Long, James A. Mailliard, H E Windschitl
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 6(5)
A randomized clinical trial was performed to determine if combination hormonal therapy with tamoxifen (TAM) and fluoxymesterone (FLU) was more efficacious than TAM alone for the treatment of postmenopausal women with metastatic breast cancer. Patient
Autor:
L K Everson, JN Ingle, Harry S. Wieand, S A Cullinan, D I Twito, James E. Krook, Jan Martin, Lester E. Wold, J K Paulsen, H J Votava
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 6(9)
Following mastectomy for node-positive breast cancer, 261 postmenopausal women were randomized to observation or adjuvant treatment with cyclophosphamide, fluorouracil, prednisone (CFP) alone or combined with tamoxifen (T). Doses used were: C, 150 mg